We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Enhanced Immune System Activity Prevents Tumor Growth in Aged Mice

By LabMedica International staff writers
Posted on 23 Apr 2012
Results obtained from studies carried out on mice indicate that it may be possible to stimulate the immune system of elderly individuals so that they become able to respond to anticancer therapy in a manner similar to younger subjects.

Modulating the activity of T regulatory (Treg) cells, which are components of the immune system that suppress immune responses of other cells and act as an important “self-check” built into the immune system to prevent excessive reactions, has been shown to increase the success of chemotherapy in young subjects but not in their elderly counterparts.

To explain this finding, investigators at the University of Texas Health Science Center (San Antonio, USA) worked with selected young and aged mouse populations. More...
They confirmed that depletion of Tregs improved immune response in young animals without benefiting the elderly mice. However, results published in the April 15, 2012, issue of the journal Cancer Research, explained the reason for this.

Depletion of Treg activity in the elderly mice caused a massive increase in another type of immune suppressor cell: myeloid-derived suppressor cells (MDSCs). These cells, which do not proliferate in the young animals, maintained the relative inefficiency of the aged immune system. Treating the aged mice with both a drug to block Treg activity and a monoclonal antibody that caused MDSC depletion improved tumor-specific immunity and reduced melanoma tumor growth in the aged mice.

“We have shown that an aged immune system can combat cancer just as well as a young one if you remove the impediments to successful immunity, which are different that those in younger hosts,” said senior author Dr. Tyler Curiel, professor of medicine at the University of Texas Health Science Center. “We have shown that if you test all your immune therapy just in young mice and young people, you will never learn how it works in older patients — the ones most at risk for cancer. You might conclude that drugs do not work in aged hosts, when they do. But they have to be combined with some help.”

While this approach was successful for treating melanoma, a different monoclonal antibody was required for colon cancer.

“The details were different in colon cancer. The bad immune cells that increased in the aged mice and how they were knocked down by the drugs were different than in melanoma,” said Dr. Curiel. “But the result was the same — we identified a drug combination that was highly effective in the aged mice. It is a bit complicated, but it is possible to put into practice, and because these approaches could be so much more specific and so much better tolerated than conventional chemotherapy, it is well worth pursuing.”

Related Links:
University of Texas Health Science Center


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: ELITechGroup’s unique Real-Time PCR technologies include the revolutionary Minor Groove Binder (Photo courtesy of ELITechGroup)

ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases

Molecular testing has become central to diagnosing and monitoring infectious diseases by analyzing genetic information. The use of PCR during the COVID-19 pandemic showed its value, but traditional systems... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.